Questions
Straight answers before you spend a meeting on it
What we own, how we license, what we turn down, and what we expect from anyone who brings us work.
How do the five operating units work together?
They are not an assembly line. IP turns observations into hypotheses and tests. Press makes the argument inspectable and tests whether people understand or use it. Capital asks whether money should move and searches for founders already pursuing it. Studios runs the cheapest useful experiment when no better-positioned builder exists. Network finds the people needed throughout. Every result returns evidence to the original thesis, followed by a decision to continue, change, back someone else, build it ourselves, or stop.
What do we actually own?
Original research, and everything it turns into. That means standing research pillars, peer-reviewed papers published with collaborators, dated research notes, patents and pending applications, published defensive disclosures, the trademarks we use in market, trade secrets, datasets, and equity in the companies Studios builds. The filings cluster in clinical workflow and care coordination, medical device data and control, clinical trials operations, records authorization and insurance evidence, digital payments and marketplaces, precision education and training, credentialing, and metrics and telemetry. The patent register lists every granted and pending filing with its number and status.
Do you publish the research, or only patent it?
Both, and the publishing usually comes first. Research pillars carry the open questions, papers go into the peer-reviewed literature with collaborators and are listed with their DOI, and notes date the design patterns and operating theories as they are worked out. We file only where a right changes what we or a licensee can build, and publish a defensive disclosure where it does not.
Is the portfolio available for license?
Yes. We license on field-of-use terms (for example, remote patient monitoring but not trials management) with diligence obligations and clear reversion. Licenses go to health systems, device makers, insurers, research organizations, platform operators, and integrators who will deploy the technology, not to parties who only want to hold it. Trademark use is licensed separately and only alongside the method or service it names.
Why publish a defensive disclosure instead of filing a patent?
Because a patent is worth its maintenance cost only when exclusivity changes what somebody can do. A device interoperability claim usually clears that bar. A scheduling improvement a competitor could design around in a week usually does not, so we publish it, put it in the prior art, and keep the ground open for everyone including ourselves.
Do you review outside inventions?
We do, on stated terms. The submission page says what we accept and what happens next. Send the non-confidential description first. Do not send confidential material until terms are signed in writing.
How do you think about AI?
The easy question is whether AI does today's work faster or with fewer people, and that is worth real money. The question we ask across all five units is which entirely new forms of work become possible. A referral function that reads every chart the day it arrives and routes the case to the clinician who can actually take it. A device program whose submission evidence assembles itself from live telemetry. A trial that checks eligibility continuously instead of at enrollment. Nobody was staffed to do any of those. That is what we file on, fund, publish, and build.
How do you decide what to fund?
The idea has to survive a test against real operating data before any money moves. Capital also searches for founders and companies already pursuing the thesis. If somebody else has stronger evidence, customer access, distribution, or execution, the firm can back them rather than recreate the work. Every position has a bounded size, one owner, and a review date set at commitment.
What kinds of problems do you not take?
Savings estimates that only work if a hospital changes its staffing model. Device software nobody has run past a regulatory reviewer. Insurance analytics that fall apart on production data. Proposals that need a procurement path the buyer does not have. We say no to those early rather than slowly.
How quickly do you respond?
Within ten business days for a first read on a well-formed submission. Well-formed means it states the result, the data behind it, and the test that would prove it wrong.
